Develop novel therapies for neuropsychiatric disorders. Conduct preclinical and clinical research to evaluate drug candidates. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 103% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Debt is low and cash is strong; the finances stand solid.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Sales are growing strongly for its sector.
Clearly below the class average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
An investor who bought at the very peak is down 98% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 103% a year on average.
Sales run at $15.6M a year. A small number, but proof the product has real buyers.
There is $21.6M in the vault; even if every debt were paid off, $21.4M would remain.
A loss of $370K against $15.6M in annual sales.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 21/100. For a turnaround signal, the stock first needs to close the gap with the market.
On our five-subject report card, NEUP sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: NEUP is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Not covered, because the filings we hold do not carry it: the revenue breakdown.